Copy
View this email in your browser

May is National Osteoporosis Month!


Join ASBMR in recognizing National Osteoporosis Month in May. This week we are highlighting the Call to Action: Addressing the Crisis in the Treatment of Osteoporosis, which addresses the alarming facts around the decline in treatment of this disease and calls for the need to educate the public and clinicians on the dangers of ignoring the impact of this disease. Let us know how you are working to address the crisis in the treatment of osteoporosis by sharing your patient stories, lab pictures, quotes, or facts to asbmr@asbmr.org! For more information on what ASBMR is doing throughout National Osteoporosis Month, click here.

Exciting News for the Bone Field: New Osteoporosis Treatment Approved by FDA


Last Friday the FDA approved a new anabolic therapy drug, TYMLOSTM (abaloparatide) developed by Radius Health. This is exciting news for the bone field as this is the first new osteoporosis treatment drug approved in over seven years. The FDA's approval of TYMLOS was based on results at 18 months from the landmark ACTIVE trial and first six months of ACTIVExtend trial that demonstrated consistent significant and rapid reductions in the risk of vertebral and nonvertebral fractures regardless of age, years since menopause, presence or absence of prior fracture (vertebral or nonvertebral) and bone mineral density (BMD) at baseline.

In-Memoriam: Adele Boskey, Ph.D.


It is with great sadness that we announce the passing of long-time member Adele Boskey, Ph.D., a senior scientist at Hospital for Special Surgery (HSS). Dr. Boskey was a pioneer in the bone mineralization field. Among her many discoveries and contributions to the field, Dr. Boskey was a pioneer in characterizing bone mineral changes in skeletal diseases such as osteoporosis and rickets. She was the 2015 recipient of the ASBMR Lawrence G. Raisz Esteemed Award for outstanding achievements in preclinical translational research in the bone and mineral field. Her recent work suggests that measuring bone quality, rather than bone density, promises greater accuracy and could predict what characteristics of bone put patients at risk of fracture. A lifelong volunteer and mentor, Dr. Boskey served many years on various committees and boards in ASBMR, ORS, IADR, NOF, AAOS, and OIF. A recognized mentor of countless grad students, postdocs, and early career scientists, Dr. Boskey was known for generously giving her time and expertise to all who asked. Join us in recognizing Dr. Boskey’s contribution to our field by leaving a note, sharing a memory, or contributing a donation in her honor.

Early-Stage Investigators: Apply for the USBJI Career Development & Grant Mentoring Program!


The United States Bone and Joint Initiative (USBJI) and Bone and Joint Canada are dedicated to increasing research of musculoskeletal diseases. The Young Investigator Initiative is a career development and grant mentoring program providing early-career investigators an opportunity to work with experienced researchers in our field to assist them in securing funding and other survival skills required for pursuing an academic career. The next workshop is scheduled to take place November 10-12, 2017, in Toronto, Ontario. Deadline to apply is July 15, 2017. Find out more about the program here.

Deep discounts on registration fees for the ASBMR Annual Meeting!

Announcing the New Rare Bone Disease Alliance
 

The Rare Bone Disease Alliance is a new organization which will work to educate physicians, expand research on rare bone disease and assist patients, patient organizations and family members. The Alliance will encourage professional, medical and scientific societies to expand their educational programs on rare bone diseases and organize its own meetings and workshops. Learn more about this initiative here.

ASBMR Members Show Their Support for Science!
 

Thank you to everyone who sent us their pictures from the March for Science held around the globe on April 22nd, 2017. We will continue to share these photographs on social media, so be sure to follow ASBMR on Facebook and Twitter! Photographed right are Dr. Paola Divieti Pajevic and Dr. Lou Gerstenfeld at the March for Science in Boston, Massachusetts, USA.
JBMR Highlights

Octreotide is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy
Diana Ovejero, Diala el-Maouche, Beth A Brillante, Azar Khosravi, Rachel I. Gafni, and Michael T Collins
Accepted manuscript online: 29 APR 2017


Leisure-Time Physical Activity and Risk of Fracture: A Cohort Study of 66,940 Men and Women
Karl Stattin, Karl Michaëlsson, Susanna C. Larsson, Alicja Wolk, and Liisa Byberg
Accepted manuscript online: 29 APR 2017

Bone Science in the News
FDA Approves Tymlos for Osteoporosis in Postmenopausal Women
Managed Care Magazine, May 1, 2017

How do you get the most out of a mentor–mentee relationship?
Healio, May 1, 2017
 
Events Calendar
May 13 - 16, 2017
ECTS 2017 - 44th European Calcified Tissue Society Congress
Salzburg, Austria
 
May 20 - 23, 2017
19th European Congress of Endocrinology
Lisboa, Portugal

May 28 – June 1, 2017

12th ICCBMT Conference
Potsdam, Germany

 
Contact ASBMR
ASBMR Business Office
2025 M Street, NW
Suite 800
Washington, DC 20036-3309 USA
Tel.: +1 (202) 367-1161
Fax: +1 (202) 367-2161
Email: asbmr@asbmr.org


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list